Skip to content Skip to footer
Subscribe Now
WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (March 03, 2025 – March 07, 2025) 

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars, Animal Health & DigiHealth. Check out our full report below:    GSK Presents Pooled Analysis from P-III (ANCHOR-1 & 2) Trial of Depemokimab for CRSwNP at AAAAI/WAO Joint Congress 2025  Read More: GSK  Daiichi Sankyo Reports Interim Data of P-III (DESTINY-Gastric04) Study…
March 7, 2025

Read more

AbbVie & Gubra
NEWS

AbbVie Enters into a Global License Agreement with Gubra to Develop & Commercialize GUB014295 to Treat Obesity

Shots: AbbVie and Gubra entered into a global license agreement to develop & commercialize GUB014295, a potential long-acting amylin analog for obesity treatment As per the deal, AbbVie will lead GUB014295's global development & commercialization, whereas Gubra will get $350M upfront, up to $1.875B development, commercial, sales milestones, with tiered royalties; transaction closure is…
March 4, 2025

Read more

Magnet Biomedicine & Eli Lilly
NEWS

Magnet Biomedicine Partners with Eli Lilly to Advance Molecular Glue Therapeutics in Oncology

Shots: Magnet Biomedicine & Eli Lilly have entered into a collaboration & license agreement to identify, develop & commercialize molecular glue therapeutics in oncology using Magnet's TrueGlue discovery platform As per the deal, Magnet will get ~$40M in upfront, near-term payments & equity, plus more than $1.25B in milestones across development, regulatory, & commercial…
March 3, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (February 24, 2025 – February 28, 2025)

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars, Animal Health & DigiHealth. Check out our full report below:    Estrella Immunopharma Reports the Approval to Start a Higher Dose Cohort After the Completion of First Dose Cohort in STARLIGHT-1 Study  Read More: Estrella Immunopharma  Regeneron Presents P-I/II (CHORD) Trial Data…
February 28, 2025

Read more

Foresight Diagnostic & Allogene Therapeutics
NEWS

Foresight Diagnostic & Allogene Therapeutics Extend Collaboration to Develop Minimal Residual Disease (MRD) Assay

Shots: Foresight & Allogene have expanded their strategic collaboration to develop minimal residual disease (MRD) assay as companion diagnostic to identify candidates for Allogene's ALPHA3 trial assessing cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma (LBCL) pts As per the collaboration, Allogene & Foresight will develop Foresight's MRD assay in the EU, UK, Canada &…
February 28, 2025

Read more

Takeda & BridGene Biosciences
NEWS

Takeda Partners with BridGene Biosciences to Identify Novel Small Molecules in Immunology and Neurology

Shots: Takeda has entered into strategic collaboration & licensing agreement with BridGene bioscience to identify novel small molecules in immunology & neurology As per the terms, Takeda will gain exclusive rights to develop & commercialize products arising from the deal in exchange for $46M including upfront & preclinical milestone, plus additional ~$770M in clinical…
February 26, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (February 17th, 2025 – February 21th, 2025) 

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Animal Health, COVID 19 & Biosimilars. Check out our full report below:      AstraZeneca Presents Post-Hoc Data from P-III (NIAGARA) Trial of Imfinzi in Muscle-Invasive Bladder Cancer Patients regardless of Complete Pathology Response at ASCO GU 2025  Read More: AstraZeneca  Exelixis Presents 5-year…
February 21, 2025

Read more

Load more